Clinuvel records first A$1 million in sales

Clinuvel records first A$1 million in sales

Successful first year of drug supply to erythropoietic protoporphyria (EPP) patients under AIFA 648/96 Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it has made a successful start to its distribution of its new drug SCENESSE® (afamelanotide) to the erythropoietic protoporphyria (EPP) patient community in Italy.

First European distribution of SCENESSE®Since commencing a special access 648/96 scheme 11 months ago SCENESSE® has been distributed to approximately 40 patients in Italy to treat EPP, a severe genetic disorder designated as an ‘orphan' disease. Throughout the treatment period all patients have been followed up by EPP specialists and, significantly, no serious drug-related adverse events have been recorded. During this period the company recorded approximately A$1 million worth of sales. Clinuvel is reimbursed for the drug by the Italian health system.

Clinuvel will continue to distribute SCENESSE® under the 648/96 scheme with the intention of expanding use of the photoprotective drug among EPP patients.

Erythropoietic protoporphyria

EPP is characterised by severe phototoxicity of the skin resulting in intolerable pain, swelling, and scarring, usually of the exposed areas such as the face, hands and feet. EPP patients are often forced to lead an indoors existence, severely affecting their quality of life. Approximately 10,000 people are globally known to be affected by EPP, an estimated 4,000 across Europe. Afamelanotide was granted orphan drug status in Europe and the US for EPP in 2008.

"I am delighted by these results, and we continue to monitor these patients who repeatedly receive the drug," Clinuvel's Chief Scientific Officer, Dr Hank Agersborg said. "Our entire team is deeply affected and motivated by the numerous reports from patients expressing how the drug is changing their existence and facilitates a pain free outdoor life."

"It is now apparent that we have made the correct clinical and regulatory choices to set a precedent of how SCENESSE® is best utilised clinically", Dr Agersborg added.

"Despite this initial success, we remain vigilant in continuously analysing the effects of repeated dosing of the drug and, most importantly, the safety of our patients," Clinuvel's CEO, Dr Philippe Wolgen said.

"The transition from research to initial revenue is significant in today's markets. This earnings call five years after starting the program is an additional benchmark for all who follow the Company's evolution. I wish to publicly thank the Italian physicians for their ongoing commitment to treating porphyria. " Dr Wolgen added.

- End -

About Clinuvel Pharmaceuticals LimitedClinuvel Pharmaceuticals Ltd is a leading and innovative Australian company focused on the development of SCENESSE® (afamelanotide), its proprietary first-in-class photoprotective drug. Clinuvel has identified a number of groups of patients with a clinical need for photoprotection and one with a need for repigmentation therapy. Currently, Clinuvel is in its final stages to complete testing of SCENESSE® in Phase II and III trials in Australia, Europe and the United States. Clinuvel's ongoing focus is to demonstrate the safety and efficacy of SCENESSE®. Pending positive clinical results, Clinuvel aims to file SCENESSE® for its first market approval for the orphan indication porphyria (EPP). SCENESSE® is a registered trademark of Clinuvel Pharmaceuticals Ltd.

For more information contact:    
Australia: Clinuvel Pharmaceuticals Limited   T: +61 3 9660 4900
Europe: Clinuvel AG    T: +41 41 767 45 45
E:   [email protected]
W: http://www.clinuvel.com

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.